Semaglutide vs Tirzepatide: A Head-to-Head Data Comparison

For most patients choosing a GLP-1 weight loss drug today, the real decision is between Wegovy (semaglutide 2.4mg) and Zepbound (tirzepatide). Both are approved. Both are once-weekly injections. Both are made by major manufacturers with established supply chains. The clinically meaningful difference shows up in efficacy, and SURMOUNT-5 (Aronne et al., New England Journal of Medicine, 2025) is the trial that nailed it down.

SURMOUNT-5 randomised 751 adults with obesity, without type 2 diabetes, to either tirzepatide titrated to maximum tolerated dose (10mg or 15mg) or semaglutide titrated to 2.4mg, for 72 weeks. Tirzepatide produced a 20.2% mean body weight reduction. Semaglutide produced 13.7%. The 6.5 percentage point gap held across subgroups. Tirzepatide also produced larger reductions in waist circumference, blood pressure, and lipids.

That gap is the central finding most readers come to this question for. The rest of the picture, including mechanisms, dosing schedules, side effect profiles, cardiovascular evidence, and cost, is what determines whether the head-to-head efficacy gap should drive an actual prescribing decision. This article walks through each of those layers.

What the two compounds are

Semaglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, the incretin hormone released by L-cells in the intestine after a meal. Activating the GLP-1 receptor slows gastric emptying, increases glucose-dependent insulin secretion, suppresses glucagon release, and acts centrally on appetite pathways in the hypothalamus and brainstem. Novo Nordisk markets semaglutide as Ozempic for type 2 diabetes, Wegovy for chronic weight management, and Rybelsus as an oral diabetes treatment.

Tirzepatide (Eli Lilly's LY3298176) is a dual agonist. It activates both the GLP-1 receptor and the GIP receptor (glucose- dependent insulinotropic polypeptide). GIP is the second incretin hormone, secreted by K-cells in the duodenum. For decades GIP was assumed to drive fat storage, based on knockout mouse studies that showed GIPR-null mice were protected from diet-induced obesity. Tirzepatide's clinical performance overturned that assumption: adding GIP activation to GLP-1 activation increased weight loss rather than blunting it. The current best mechanistic explanation is that GIP receptor activity in the central nervous system amplifies the satiety signal, and that GIP improves the insulin response to GLP-1 agonism in pancreatic beta cells. Our GLP-1 vs GIP file covers the receptor biology in depth.

The pharmacological gap between the two compounds is the addition of one receptor. Both target GLP-1 with similar receptor affinity. Tirzepatide's molecule is engineered to be a balanced agonist at both GLP-1 and GIP receptors. Semaglutide has no meaningful activity at GIP. Receptor stacking adds roughly 5 to 7 percentage points of weight loss per receptor across the class, and semaglutide-to-tirzepatide is the cleanest expression of that pattern, producing about 7.6 percentage points of additional weight loss in cross-trial comparisons.

Both compounds are lipidated peptides designed for weekly dosing. Semaglutide's half-life is around 165 hours (about 7 days). Tirzepatide's is around 5 days. Both are administered as subcutaneous injections through prefilled pens, with comparable injection-site experience.

What the research says

Three trials matter most for this comparison. SURMOUNT-5 is the only head-to-head. STEP 1 and SURMOUNT-1 are the foundational obesity trials for each compound.

SURMOUNT-5: the head-to-head

SURMOUNT-5 (Aronne et al., NEJM, 2025) is the cleanest data point in the comparison. The trial randomised 751 adults with obesity (without type 2 diabetes) to tirzepatide at maximum tolerated dose (10mg or 15mg weekly) or semaglutide titrated to 2.4mg weekly, for 72 weeks. Mean body weight change was -20.2% with tirzepatide versus -13.7% with semaglutide. The proportion of participants reaching 15% weight loss was 64.6% on tirzepatide and 40.1% on semaglutide. The proportion reaching 25% weight loss was 31.6% on tirzepatide and 16.1% on semaglutide.

Secondary endpoints went the same direction. Waist circumference fell by an additional 5.6 cm on tirzepatide. Systolic blood pressure dropped by an extra 3 mmHg. Lipid profile improvements were larger across LDL, triglycerides, and non-HDL cholesterol. The trial removed cross-trial population differences as a confound, which is what makes its readout so much more useful than comparing STEP 1 and SURMOUNT-1 separately.

STEP 1 and the broader semaglutide programme

STEP 1 (Wilding et al., NEJM, 2021; NCT03548935) randomised 1,961 adults with overweight or obesity, without diabetes, to semaglutide 2.4mg or placebo for 68 weeks. Mean body weight change was -14.9% with semaglutide versus -2.4% with placebo. STEP 2 tested the same dose in adults with type 2 diabetes (-9.6%). STEP 3 added intensive behavioural therapy (-16.0%). STEP 5 extended treatment to 104 weeks and reported sustained reductions of around -15.2%.

The SELECT trial (Lincoff et al., NEJM, 2023) is the piece of the semaglutide evidence base that tirzepatide cannot yet match. Across 17,604 adults with established cardiovascular disease and overweight or obesity (without diabetes), semaglutide 2.4mg produced a 20% relative risk reduction in the composite endpoint of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke over a median 40 months. SELECT changed how the GLP-1 class is positioned in cardiology and remains the clearest outcomes evidence in the weight-management space.

SURMOUNT-1 and the tirzepatide obesity programme

SURMOUNT-1 (Jastreboff et al., NEJM, 2022; NCT04184622) randomised 2,539 adults with obesity to tirzepatide 5mg, 10mg, 15mg, or placebo for 72 weeks. The 15mg dose produced -22.5% body weight reduction versus -2.4% with placebo. SURMOUNT-2 tested tirzepatide in adults with obesity and type 2 diabetes (-15.7% at 15mg). SURMOUNT-3 layered on intensive lifestyle therapy and pushed weight loss to roughly 26% combined. SURMOUNT-4 tested withdrawal: stopping tirzepatide led to substantial weight regain over the following year, mirroring the STEP 4 finding with semaglutide.

Tirzepatide's cardiovascular outcomes data is still pending. SURPASS-CVOT, the dedicated trial in adults with type 2 diabetes and high cardiovascular risk, is expected to read out in 2026 or 2027. Until then, semaglutide holds the only published outcomes advantage in the comparison.

Practical breakdown: dosing, administration, tolerability

Both drugs are once-weekly subcutaneous injections, both require stepwise titration to manage gastrointestinal side effects, and both come in prefilled pen devices. The titration schedules differ.

Semaglutide titration (Wegovy)

• Weeks 1 to 4: 0.25mg weekly
• Weeks 5 to 8: 0.5mg weekly
• Weeks 9 to 12: 1.0mg weekly
• Weeks 13 to 16: 1.7mg weekly
• Week 17 onward: 2.4mg weekly (maintenance)

Tirzepatide titration (Zepbound)

• Weeks 1 to 4: 2.5mg weekly
• Weeks 5 to 8: 5mg weekly
• Weeks 9 to 12: 7.5mg weekly
• Weeks 13 to 16: 10mg weekly
• Weeks 17 to 20: 12.5mg weekly
• Week 21 onward: 15mg weekly (maximum maintenance)

Tirzepatide's full titration is 20 weeks against semaglutide's 16, because there are more dose steps and the maintenance ceiling is higher. In practice, many tirzepatide patients hold at 5mg, 10mg, or 12.5mg rather than pushing to 15mg, particularly if weight loss is on track and side effects are manageable. Semaglutide patients have one maintenance dose (2.4mg) to aim for, which simplifies the back end of the titration.

Common adverse events in SURMOUNT-5 were broadly similar between the arms at class-typical rates: nausea (44.0% tirzepatide vs 50.0% semaglutide), diarrhea (24.7% vs 20.4%), vomiting (20.7% vs 21.1%), and constipation (21.6% vs 17.6%). Nausea was actually slightly less common on tirzepatide than semaglutide, which surprised some clinicians. Discontinuation due to adverse events was 6.1% on tirzepatide and 8.0% on semaglutide. Neither drug produced a novel safety signal in this trial.

Two practical notes worth flagging. First, slower titration consistently improves tolerability for both drugs. Clinicians often extend each step by an extra two to four weeks for patients sensitive to nausea, particularly during the first 8 weeks. Second, tirzepatide's maintenance dose is a clinical decision rather than a fixed protocol. The 5mg, 10mg, and 12.5mg doses are all approved for chronic use, and the tradeoff between extra weight loss at higher doses and worsening side effects is real. Semaglutide does not offer that flexibility because 2.4mg is the only approved obesity maintenance dose.

Direct comparison table

How to think about the choice

For a patient with no cardiovascular history and a primary goal of weight loss, the SURMOUNT-5 data points clearly toward tirzepatide. A 6.5 percentage point advantage is clinically meaningful: at a baseline weight of 100 kg, that's 6.5 additional kilograms over 72 weeks, with similar tolerability and a slightly lower discontinuation rate. Tirzepatide also costs roughly $290 per month less at US list prices.

For a patient with established cardiovascular disease, the calculation flips. SELECT showed semaglutide reduces major adverse cardiovascular events by 20% in this population. No equivalent outcomes data exists for tirzepatide yet. SURPASS-CVOT is expected to report in 2026 or 2027. Until that readout lands, cardiologists prescribing for cardiovascular protection will generally default to semaglutide. The weight-loss gap is real, but a documented MACE reduction in a 17,604-patient outcomes trial is currently the stronger evidence base for the relevant endpoint.

For a patient with type 2 diabetes, both drugs have strong indications. Semaglutide's SUSTAIN trials and tirzepatide's SURPASS trials both produced large A1C reductions, with tirzepatide showing modestly larger glucose lowering at top doses (SURPASS-2 was the head-to-head in diabetes, where tirzepatide outperformed semaglutide 1mg). The choice in diabetes usually comes down to insurance coverage, prescribing habit, and patient tolerability rather than a clear efficacy signal.

Cost and availability are the unglamorous part of the decision. Wegovy lists at around $1,350 per month, Zepbound at around $1,060. Manufacturer savings cards bring out-of-pocket costs substantially lower for commercially insured patients, often to $25 or $0 per month with eligible plans. Medicare does not cover either drug for obesity. Both manufacturers experienced supply shortages in 2023 and 2024 that allowed widespread compounding; the FDA designated semaglutide as resolved in late 2024 and tirzepatide in early 2025, ending the legal basis for routine 503A compounding of either compound.

The longer-term context is that this comparison is unlikely to stay static. Retatrutide's TRIUMPH-4 readout (28.7% at 12mg / 68 weeks) suggests the next tier of weight-loss efficacy is on the way, with retatrutide adding a third receptor (glucagon) on top of GLP-1 and GIP. Our triple vs dual agonism file covers the receptor progression in detail. The GLP-1 comparison chart 2026 puts every approved and late-stage compound on the same axes.

Frequently Asked Questions